U.S. Markets close in 1 hr 58 mins
  • S&P 500

    4,581.49
    +6.70 (+0.15%)
     
  • Dow 30

    35,685.73
    -71.15 (-0.20%)
     
  • Nasdaq

    15,354.13
    +118.42 (+0.78%)
     
  • Russell 2000

    2,271.88
    -24.20 (-1.05%)
     
  • Gold

    1,799.00
    +5.60 (+0.31%)
     
  • EUR/USD

    1.1618
    +0.0016 (+0.1394%)
     
  • 10-Yr Bond

    1.5330
    -0.0860 (-5.31%)
     
  • Vix

    15.56
    -0.42 (-2.63%)
     
  • GBP/USD

    1.3757
    -0.0007 (-0.0481%)
     
  • USD/JPY

    113.7970
    -0.3320 (-0.2909%)
     
  • BTC-USD

    59,035.08
    -3,459.07 (-5.54%)
     
  • CMC Crypto 200

    1,414.69
    -59.64 (-4.05%)
     
  • FTSE 100

    7,253.27
    -24.35 (-0.33%)
     
  • Nikkei 225

    29,098.24
    -7.76 (-0.03%)
     

ERYTECH Announces the Availability of its Half-Year Financial Report 2021

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

ERYTECH Announces the Availability
of its Half-Year Financial Report 2021

Lyon (France) and Cambridge, MA (U.S.), Septembre 22, 2021ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced that it had filed with the Autorité des Marchés Financiers (AMF) its half-year report for the six-month period ended June 30, 2021.

The half-year financial report is available in the Investors section of the Company’s corporate website (wwww.erytech.com).

About ERYTECH

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival.

The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cells’ altered asparagine and glutamine metabolism. Eryaspase is in a Phase 3 clinical development for the treatment of second-line pancreatic cancer, which is fully enrolled and expected to read out top-line results in Q4 2021, and in an ongoing Phase 2 for the treatment of triple-negative breast cancer. An investigator sponsored Phase 2 trial (IST) in acute lymphoblastic leukemia recently reported positive results, and a Phase 1 IST in 1L advanced pancreatic cancer is ongoing.

Eryaspase received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of advanced pancreatic cancer and treatment of acute lymphoblastic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase). The FDA and the European Medicines Agency have granted eryaspase orphan drug status for the treatment of pancreatic cancer and ALL.

ERYTECH produces its product candidates for treatment of patients in Europe at its GMP-approved manufacturing site in Lyon, France, and for patients in the United States at its GMP manufacturing site in Princeton, New Jersey, USA. Eryaspase is not an approved medicine.

ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.
For more information, please visit www.erytech.com

CONTACTS

ERYTECH
Eric Soyer
CFO & COO

LifeSci Advisors, LLC
Corey Davis, Ph.D.
Investor Relations

NewCap
Mathilde Bohin / Louis-Victor Delouvrier
Investor relations
Nicolas Merigeau
Media relations



+33 4 78 74 44 38
investors@ERYTECH.com



+1 (212) 915 - 2577
cdavis@lifesciadvisors.com



+33 1 44 71 94 94
ERYTECH@newcap.eu



Attachment